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ARTICLE
Type I interferon-mediated autoinﬂammation due
to DNase II deﬁciency
Mathieu P. Rodero et al.
Microbial nucleic acid recognition serves as the major stimulus to an antiviral response,
implying a requirement to limit the misrepresentation of self nucleic acids as non-self and the
induction of autoinﬂammation. By systematic screening using a panel of interferon-stimulated
genes we identify two siblings and a singleton variably demonstrating severe neonatal ane-
mia, membranoproliferative glomerulonephritis, liver ﬁbrosis, deforming arthropathy and
increased anti-DNA antibodies. In both families we identify biallelic mutations in DNASE2,
associated with a loss of DNase II endonuclease activity. We record increased interferon
alpha protein levels using digital ELISA, enhanced interferon signaling by RNA-Seq analysis
and constitutive upregulation of phosphorylated STAT1 and STAT3 in patient lymphocytes
and monocytes. A hematological disease transcriptomic signature and increased numbers of
erythroblasts are recorded in patient peripheral blood, suggesting that interferon might have
a particular effect on hematopoiesis. These data deﬁne a type I interferonopathy due to
DNase II deﬁciency in humans.
DOI: 10.1038/s41467-017-01932-3 OPEN
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In 1989, Charles Janeway predicted the existence of pattern-recognition receptors (PRRs) serving to detect microbialmolecular motifs distinct from self as a fundamental aspect of
immunity1. Such motifs, which must be evolutionarily essential to
the microbe so that they are not easily mutated for the ‘purpose’
of escaping a host immune response, are now recognized to
include constituents of the bacterial cell wall and the nucleic acid
component of viruses. In a vindication of the Janeway hypothesis,
a number of PRRs have been identiﬁed, including those that
detect nucleic acids in endosomal (TLR, Toll-like receptors) and
cytosolic (particularly, RIG-I, retinoic-acid-inducible gene I;
MDA5, melanoma differentiation-associated protein 5; AIM2,
absent in melanoma 2; cGAS, cyclic GMP-AMP synthase) cellular
compartments2. Indeed, it has become clear that most antiviral
responses are initiated by innate immune receptors that detect
viral nucleic acids, immediately raising the question as to how a
cell discriminates between self and non-self, given that the basic
molecular structure of DNA and RNA is conserved across spe-
cies3, 4. Study of the function of these receptors has shed light on
this issue, with their physical separation from self nucleic acids,
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Fig. 1 Clinical ﬁndings associated with bilallelic mutations in DNASE2. a Pedigrees of families F1 a and F2 b. Circles and squares indicate female and male
family members respectively. Black symbols represent family members with a homozygous mutation in DNASE2. Mut mutation, Wt wild-type, ND
genotype not determined. F1:V-2 denotes a fetus delivered in late pregnancy with hydrops fetalis, hepatosplenomegaly and petechiae. c
Membranoproliferative glomerulonephritis seen on renal biopsy (×40) of F1:V-3 at age 6 years in the absence of features of lupus nephritis. There is
increased lobulation and cellularity (stars) of the mesangial matrix associated with double contours (arrows). Similar ﬁndings were present in F2:II-4. d
Liver ﬁbrosis on biopsy (x20) of F1:V-3 at age 8 years. Similar features were also present in F2:II-4. e Non-destructive, deforming arthropathy seen in
F2:II-4 beginning at age 8 years. f Vasculitic lesion on the foot of F2:II-4 at age 13 years. g Patchy, sub-cortical white matter lesions in the parietal lobes
recorded on FLAIR imaging in F1:V-3 at age 8 years, and which were also observed in F2:II-4
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the differential modiﬁcation of endogenous vs. exogenous nucleic
acids, thresholds of receptor tolerance for endogenous nucleic
acid species and systems of self nucleic acid elimination all con-
tributing to ensure self non-immunogenicity5. However, the
observation of human autoimmune and autoinﬂammatory states
indicates that these systems are not perfect, with the Mendelian
type I interferonopathies6, 7, for example due to loss-of-function
of the cytosolic DNase TREX1 signaling through the DNA sensor
cGAS and its adapter molecule stimulator of interferon genes
(STING)8–12, highlighting the potential for type I interferon
induction by self-derived nucleic acid.
Using a screening assay to identify previously uncharacterized
inborn errors of immunity associated with enhanced type I
interferon signaling13, 14, we ascertain three patients from two
unrelated families demonstrating a spectrum of clinical features
including resolving neonatal anemia, membranoproliferative
Table 1 Clinical details of the three affected individuals with biallelic mutations in DNASE2
F1:V-1 F1:V-3 F2:II-4
Gender
(relationship)
Female (sister of F1:V-3) Male (brother of F1:V-1) Male
Current age 10 years 8 years 17 years
Current growth
status
Height-0.2 SD; weight-0.7 SD Height-2.2 SD; weight-0.9 SD Height-5.95 SD; weight-4.39 SD
Features at
presentation
Neonatal HSM, cholestatic hepatitis and
pancytopenia requiring multiple RBC and
platelet transfusions
Neonatal HSM, cholestatic hepatitis and
pancytopenia requiring multiple RBC and
platelet transfusions
Neonatal HSM, cholestatic hepatitis and
pancytopenia requiring multiple RBC and
platelet transfusions
Hematological
status
Resolving neonatal pancytopenia; mild
thrombocytopenia and neutropenia from age
10 years
Neonatal pancytopenia resolving by age
1 month; persistence of a mild
thrombocytopenia with ﬂuctuating
neutropenia, and an episode of pancytopenia
at age 4 years followed by progressive non-
regenerative normocytic anemia from 7 years
of age requiring recurrent blood transfusions
Neonatal pancytopenia resolving by age
2–3 months; normocytic anemia noted at age
8 years; bone marrow analysis showed
normal cell composition but reduced cell
numbers, considered indicative of
inﬂammatory damage
Recurrent fevers Starting at age 7 years, typically lasting 48 h,
associated with raised ESR but essentially
normal CRP
Starting at age 5 years, typically lasting 48 h,
associated with raised ESR but essentially
normal CRP
Starting at age 5 years, typically lasting
4–5 days, associated with swollen and painful
knees, elbows, feet, wrists, raised ESR and
CRP
Postnatal hepatic
disease
HSM present at age 7 years with increased
liver stiffness (no biopsy performed)
Longstanding HSM with ﬁbrotic changes
noted on biopsy at age 5 years
Liver biopsies performed in the neonatal
period (cholestatic hepatitis), and then at the
age of 3 (‘possible cirrhosis’) and 8 years
(ﬁbrosis in the absence of active
inﬂammatory inﬁltrates); normal ﬁbroscan
recorded at 17 years of age
Renal status Proteinuria recorded at age 10 years,
presumed secondary to MGN but not
biopsied
MGN without features of SLE at age 6 years
(immunoﬂuorescence staining negative for
IgA, IgM, C3 and C1q)
Proteinuria with features of MGN diagnosed
at age 8 years; normal values of C3 and C4;
proteinuria no longer apparent at age 14
years, although renal biopsy showed
immunocomplex deposition with abundant
C1q accumulation
Neurological
status
Developmentally normal Normal early motor and cognitive milestones,
now demonstrating moderate learning
difﬁculties at school; cranial MRI at age 8
years showing patchy sub-cortical white
matter hyperintensities on T2 weighted
imaging, and possible subtle calciﬁcation in
the basal ganglia
Headaches and mild learning difﬁculties;
cranial MRI at age 15 years showing small
sub-cortical white matter hyperintensities on
T2 weighted imaging
Joint disease None None Non-destructive deforming arthropathy
beginning at age 8 years, particularly affecting
the knees, hips, elbows and wrists, hands and
temporo-mandibular joints, which has been
refractory to broad-spectrum
immunosuppression, anti-IL-1 receptor, anti-
IL-1β and anti-TNFα therapies
Immune status Normal; ﬂuctuating signiﬁcant elevation of
anti-DNA antibodies
Transient B-cell lymphopenia at birth,
recurring at age 4 years, with frank
hypogammaglobulinemia from 7 years of age
requiring IVIG; progressive CD4+ and CD8+
lymphopenia ﬁrst recorded at age 6 years;
ﬂuctuating signiﬁcant elevation of anti-DNA
antibodies
Mild lymphopenia; ﬂuctuating signiﬁcant
elevation of anti-DNA antibodies
Endocrinological
status
Normal IDDM from age 5 years (negative for anti-
GAD, anti-IA2, anti-Langerhans islet and anti-
ZnT8 antibodies)
Reduced response to arginine suggestive of
growth hormone deﬁciency noted at age 17
years
Skin involvement None None Lipodystrophy of the limbs and chilblain-like
lesions of the hands and feet since the age of
13 years
Current status
and treatments
Clinically asymptomatic but exhibits mild
thrombocytopenia, neutropenia and
proteinuria, as well as continued upregulation
of ISGs and ESR; not currently treated, but
due to start MMF and steroids in view of
persistent proteinuria
Dependent on immunosuppression for renal
disease; MMF, low dose steroids, IVIG
replacement therapy, insulin, and RBC
transfusions
Continued joint disease with Cushingoid
features and failure to thrive, without signs of
puberty; hydroxychloroquine, mepacrine,
abatacept and low-dose steroids
CRP C-reactive protein; ESR erythrocyte sedimentation rate; HSM hepatosplenomegaly; IDDM insulin-dependent diabetes mellitus; ISGs interferon-stimulated genes; IVIG intravenous immunoglobulin;
MGN membranoproliferative glomerulonephritis; MMF mycophenolate mofetil; MRI magnetic resonance imaging; NR not recorded; RBC red blood cell; SLE systemic lupus erythematosus
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glomerulonephritis, liver ﬁbrosis, deforming arthropathy and
increased anti-DNA antibodies. We present data to show that the
disease in these patients is due to biallelic loss-of-function
mutations in DNASE2, encoding the lysosomal endonuclease
DNase II, leading to an autoinﬂammatory state including mark-
edly enhanced type I interferon signaling. DNase II plays a central
role in the clearance of nucleic acids generated through apoptosis
and the phagocytosis of maturating erythroblast nuclei, so that
the absence of DNase II in mice leads to a chronic activation of
type I interferon signaling mediated through the cGAS STING)
pathway15. As such, the cases presented here further emphasize
the pathological consequences of dysregulated nucleic acid sen-
sing in the human context.
Results
Clinical phenotype. By systematic screening of patients with
putative inﬂammatory phenotypes, we ascertained a female–male
sibling pair born to consanguineous parents of Algerian ancestry
(Fig. 1a), and a singleton born to a European Italian couple who
were not knowingly related (Fig. 1b), demonstrating increased
expression of a panel of six interferon-stimulated genes (ISGs)
(IFI27, IFI44L, IFIT1, ISG15, RSAD2, and SIGLEC1) (Supple-
mentary Figs. 1 and 2). Clinical and laboratory details of the three
affected individuals are provided in Table 1 and Supplementary
Tables 1–5. All three children demonstrated severe non-
regenerative anemia and thrombocytopenia at birth necessitat-
ing red blood cell and platelet transfusions, together with hepa-
tosplenomegaly and cholestatic hepatitis which resolved in the
ﬁrst few weeks of life. All three patients also experienced recur-
rent fevers starting between 5 and 7 years of age, and the onset of
proteinuria between the ages of 6 and 10 years, with membra-
noproliferative glomerulonephritis documented in the younger
affected child from Family 1 (F1; F1:V-3) and the proband from
Family 2 (F2; F2:II-4) (Fig. 1c). Both these children also subse-
quently developed hepatosplenomegaly with ﬁbrosis identiﬁed on
liver biopsy (Fig. 1d and Supplementary Fig. 3). F1:V-3 developed
antibody-negative insulin-dependent diabetes mellitus at 5 years
of age, as well as persistent non-regenerative anemia and hypo-
gammaglobulinemia necessitating repeated blood transfusions
and intravenous immunoglobulin beginning at 7 years of age.
Starting at 8 years of age, F2:II-4 experienced the onset of a non-
destructive, deforming arthropathy which has been refractory to
broad-spectrum immunosuppression, anti-IL-1 receptor, anti-IL-
1β and anti-TNFα therapies (Fig. 1e). At the age of 13 years, this
patient also developed vasculitic skin lesions (Fig. 1f). F1:V-3 and
F2:II-4 were recorded to show non-speciﬁc sub-cortical white
matter lesions on cerebral imaging in the absence of overt neu-
rological signs, although F1:V-3 exhibited learning difﬁculties
necessitating extra help at school (Fig. 1g). At the age of 10 years,
the oldest child from Family 1 (F1:V-I) is essentially clinically
asymptomatic, although she has recently developed signiﬁcant
proteinuria. All three patients demonstrated a persistent increase
in erythrocyte sedimentation rate (ESR), whilst C-reactive protein
(CRP) levels were within the normal range in both affected
individuals from family F1 but more frequently elevated in F2:II-4
(Supplementary Fig. 4). Serial testing also revealed ﬂuctuating
signiﬁcant titers of anti-DNA antibodies in all three affected
individuals.
Genetic analysis and identiﬁcation of mutations in DNASE2.
We performed whole-exome sequencing using DNA from the
three patients and their parents, and we ﬁltered coding variants
against allele frequencies in public and local databases. We
recorded a homozygous c.347G>C variation in DNASE2 in the
two affected individuals from family F1, and a homozygous
c.362A>T variant in the same gene in the proband of family F2
(Fig. 2a). Both sets of parents were heterozygous for the relevant
familial variant, and all four unaffected siblings from both
families were either homozygous or heterozygous wild type
(Supplementary Fig. 5).
The c.347G>C transversion leads to the substitution of a
glycine for an alanine at amino acid position 116 (p.Gly116Ala/
G116A) of the human DNase II protein, whilst the c.362A>T
transversion results in the substitution of an aspartate by a valine
at position 121 (p.Asp121Val/D121V). The glycine residue at 116
and the aspartate residue at 121 are highly conserved (Fig. 2b and
Supplementary Fig. 6), and both substitutions, neither of which is
recorded on the gnomAD database comprising >245,000 alleles at
these positions, are predicted as damaging according to a variety
of in silico algorithms (Supplementary Table 6 and Supplemen-
tary Fig. 7).
The G at base 347 of the cDNA is the ﬁrst nucleotide of exon 4,
and is thus predicted to act as an acceptor for RNA splicing, a
process likely affected by the G>C transversion16. Sequencing of
cDNA from peripheral blood mononuclear cells (PBMCs) of F1:
V-1 and F1:V-3 conﬁrmed an in-frame deletion of exon 4,
encoding amino acids 116 to 171 (Fig. 2c). In the two affected
siblings, gel electrophoresis of cDNA product ampliﬁed across
exon 4 of DNASE2 revealed a shorter band compared to controls,
as well as a faint wild-type band. F1:IV-2 demonstrated a wild-
type band and a band at the same size as seen in her two affected
children, consistent with her heterozygous status (Fig. 2d). qPCR
of cDNA using TAQman probes speciﬁc for exons 4 and 5 of
DNASE2 supported these data, suggesting a degree of leaky
splicing and the production of some non-deleted product in F1:
V-1 and F1:V-3 (Fig. 2e). Furthermore, sequencing of the faint
band of wild-type size obtained by PCR of cDNA from F1:V-1
indicated the presence of full-length transcript including the
c.347G>C variant (Supplementary Fig. 8). Western blot analysis
of macrophage-enriched cells from F1:IV-2 revealed only a single
band at the size of the full-length protein, indicating that the
deleted product was not translated or was unstable in this cell
type (Supplementary Fig. 9). Sufﬁcient material was not available
for a similar analysis in the affected patients, and blotting of
protein extracts derived from ﬁbroblasts did not produce
interpretable data.
Mutations in DNASE2 result in a loss of DNase II activity. The
aspartate at position 121 falls within the N terminal phospholi-
pase D domain which, together with the histidine at position 130,
likely plays an important role in DNase II catalytic function17.
Both of these residues are encoded by exon 4 of DNASE2, and
would therefore be absent in the mis-spliced transcripts resulting
from the c.347G>C mutation in family F1 (Supplementary
Fig. 10). Expression in HEK293T cells of mutant constructs
lacking exon 4, or with the c.347G>C (Gly116Ala) or the
c.362A>T (Asp121Val) substitutions, was associated with
reduced levels of DNase II activity against circularized plasmid
DNA compared to controls (WT) (Fig. 3a–c). Furthermore,
lysates of ﬁbroblasts from F1:V-1 and F2:II-4 demonstrated a
marked reduction of DNase II activity against the same substrate;
DNase II activity in these cells could be restored by expression of
constructs coding for wild-type protein (Fig. 3d). Concordant
data were obtained after siRNA knockdown of DNASE2 in
control ﬁbroblasts (Supplementary Fig. 11). Taken together, these
data provide validation of the pathogenicity of the DNASE2
variants recorded in each family.
Loss of DNase II activity induces interferon signaling. DNase II
null mice accumulate undigested DNA in the lysosomes of
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macrophages which then chronically activates type I interferon
production to result in a lethal perinatal anemia18–20. In contrast,
DNase2 knockout mice also lacking the type I interferon receptor
(Ifnar1) live beyond birth, but develop a cytokine-dependent
chronic polyarthritis21, 22. Both the embryonic and post-natal
phenotypes are cGAS and STING-dependent12, 23.
Whole-genome expression analysis of RNA (RNA-Seq) con-
ﬁrmed the results of our screening assay, demonstrating a global
upregulation of ISGs in whole blood from F1:V-1 and F1:V-3 as
seen in patients with gain-of-function mutations in STING or loss
of TREX1 (DNase III) activity (Fig. 4a and Supplementary
Table 7). Combining high-afﬁnity pan-interferon alpha anti-
bodies with single-molecule array (Simoa) digital ELISA technol-
ogy24, 25, we recorded increased levels of interferon alpha protein
in serum and plasma from all three patients, comparable to levels
observed in other type I interferonopathies26 (Fig. 4b). Over-
expression of the ISGs IFIT1, IFI16 and IFI27 in unstimulated
patient ﬁbroblasts could be reversed by lentiviral transduction of
wild-type DNase II (Supplementary Fig. 12), and siRNA knock-
down of DNASE2 in control ﬁbroblasts resulted in increased ISG
expression similar to that observed in patient cells (Supplemen-
tary Fig. 13). As has been described for patients mutated in
TMEM17326, an analysis of cultured cell subpopulations
indicated that monocytes were a major source of circulating
interferon (Fig. 4c). Unstimulated CD3 positive T cells and CD14
positive monocytes demonstrated increased phosphorylation of
STAT1 and STAT3 (Fig. 4d and Supplementary Fig. 14).
Treatment of a cell fraction enriched for patient lymphocytes
(non-adherent cells) led to a reduction of STAT1 and STAT3
phosphorylation (Fig. 4e), and a decrease in ISG expression in
G116A  D121V
H.sapiens GHTKGVLLLDHDGG
P.troglodytes GHTKGVLLLDHDGG
N.leucogenys   GHTKGVLLFDHDGG
R.norvegicus  GHTKGVLLLDQEGG
M.musculus GHTKGVLLLDQEGG
C.familiaris GHTKGVLLLDQEGG
X.laevis GHTKGMLLLDKKQG
T.nigroviridis  GHTKGVVLLDKHQG
D.rerio GHTKGVVVFDKEQG
D.melanogaster GHAKGVVASDGETA
C.elegans GHTKGTIFFDGTSG
a
EXON 3 EXON 5
cDNA
Exon 3 Exon 4 Exon 5
Reference
protein
Predicted
protein
2.5
2.0
1.5
R
Q 
va
lue
1.0
0.5
0.0
Co
ntr
ol 1
Co
ntr
ol 2
Co
ntr
ol 3
Co
ntr
ol 4
Co
ntr
ol 5
F1
:IV
-2
F1
:V-
1
F1
:V-
3
c.347G>C
p.Gly116Ala
1 29 89 116 171 237 361
c.362A>T
p.Asp121Val
1 2 3 4 5 6
b c
d
e
Control
Co
ntr
ol 3
F1
: V
-1
DN
as
e2
–
/–
F1
: V
-3
DN
as
e2
–
/–
F1
: IV
-2
DN
as
e2
+/–
Patients Mother
GeneRuler
100 bp
DNA ladder
400
200
600
500
300
100
700
800
900
1000
EXON 4
EXON 5
200 210 220
Fig. 2 Genetic ﬁndings associated with bilallelic mutations in DNASE2. a Intron/exon structure of the DNASE2 gene, with the splicing-out of exon 4
consequent upon the c.347G>C mutation indicated by the lines above the ﬁgure. Coding exons are represented by the black boxes, with the respective
amino acid count given below each exon. The positions of the two homozygous mutations are shown. b A CLUSTAL Omega alignment of DNase II
homologs illustrates the strict evolutionary conservation of the homozygous mutations identiﬁed in families F1 and F2 (boxed in red). c An
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product ampliﬁed across exon 4 of DNASE2 from a control, F1:V-1, F1:V-3 and F1:IV-2 (the mother of the two affected individuals in this family). F1:IV-
2 shows a wild-type band as observed in the control, and a smaller band as seen in her homozygous mutant offspring. A second, fainter, wild-type band is
also present in the affected patients, best seen after longer exposure, likely representing a degree of leaky splicing. e qPCR of cDNA using a TAQman probe
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both adherent and non-adherent (monocyte and lymphocyte
enriched, respectively) cells (Fig. 4f and Supplementary Figs. 14
and 15).
Loss of DNase II activity results in an inﬂammatory state.
Mouse data emphasize the induction of both interferon and non-
interferon-mediated inﬂammation in the absence of DNase II,
highlighting a role for TNFα, IL-1β, and IL-6 in the pathology of
the postnatal arthritis observed in the DNase2−/− Ifnar1−/−
model21, 22. Multiplex analysis using serum from F1:V-1, F1:V-3
and F2:II-4 demonstrated an overlap of cytokine and chemokine
protein expression induced by loss of DNase II activity and
activation of STING, distinct from the inﬂammatory state related
to mutations in TREX1 (Fig. 5a). Single analyte ELISA assays
using serum from F1:V-1 and F1:V-3 were consistent with the
multiplex analysis, suggesting consistently elevated protein levels
of TNFα in both patients, a more variable elevation of IL-1β, and
concentrations of IL-6 mostly reﬂecting normal physiological
levels (Fig. 5b).
Effects of DNase II loss of function on erythropoiesis. Mam-
malian deﬁnitive erythropoiesis takes place in the fetal liver and
bone marrow, where macrophages digest nuclei extruded by
developing erythroblasts27, 28. DNase2 knockout mice die in late
embryogenesis or immediately after birth due to a severe anemia.
Analysis of fetal liver in these mice reveals the accumulation of
undigested DNA from erythroblasts, and in tissues where apop-
tosis occurs during development increased numbers of macro-
phages ﬁlled with DNA are detected18, 19. In keeping with this, all
three children reported here demonstrated severe anemia and
thrombocytopenia at birth necessitating red blood cell and pla-
telet transfusions. Network pathway analysis of RNA-Seq data
obtained from F1:V-1 and F1:V-3, excluding over-expressed ISG
transcripts common to other type I interferonopathies, high-
lighted changes in the expression of genes related to
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4 compared to cells from a healthy control, which could be rescued by transfection of a construct coding for wild-type (WT) protein
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erythropoiesis compared to controls and patients with gain-of-
function mutations in STING (Fig. 6a–c and Supplementary
Fig. 16). Fresh blood samples from F1:V-1 and F1:V-3 demon-
strated a marked increase in the percentage of circulating ery-
throblasts, whilst the number of reticulocytes was the same as in
controls (Fig. 6d, e and Supplementary Fig. 17). These features
were suggestive of ineffective erythropoiesis, as conﬁrmed by
bone marrow cytology in F1:V-3 (Supplementary Table 8). Of
note, examination of a liver biopsy from F1:V-3 revealed
increased numbers of Kupffer cells staining for hemosiderin,
indicating increased phagocytosis of red blood cells (Fig. 6f).
Discussion
We describe here a multisystem autoinﬂammatory syndrome due
to biallelic hypomorphic mutations in DNASE2, the gene
encoding the 360 amino acid lysosomal DNase DNase II29. Each
mammalian cell carries around 6 pg of nuclear DNA, and it has
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been estimated that in humans more than 1 g of cellular DNA is
eliminated and degraded each day30. A series of elegant studies in
mice has shown that DNase II digests the DNA of apoptotic cells
and of nuclei expelled from erythroid precursors. DNase II null
mice accumulate DNA in the lysosomes of fetal liver Kupffer cells
and bone marrow macrophages20, 27, which activates type I
interferon production resulting in a lethal anemia18–20. Dnase2
knockout mice also lacking the type I interferon receptor21, or
IRF3 and IRF731, live beyond birth, but develop a chronic poly-
arthritis. Importantly, these embryonic and post-natal pheno-
types are each rescued by crossing the DNase II null mouse
against mice defective in STING23 or cGAS12, thus highlighting
the central role of TLR-independent cytosolic DNA signaling in
either situation.
All three children that we ascertained presented in the neonatal
period with life-threatening anemia and thrombocytopenia,
which resolved spontaneously within a few weeks of birth. A
similar pattern of hematological involvement has been noted in
patients with pseudo-infection syndromes due to loss-of-function
mutations in TREX132 and USP1833. Furthermore, studies in
mice have implicated endogenously produced type I interferon in
the depletion of hematopoietic progenitors during virus-induced
transient pancytopenia34. These observations, together with the
experimental data presented here, including the ﬁnding that
recombinant interferon alpha treatment of erythroid progenitors
derived from cord blood results in increased apoptosis (Supple-
mentary Fig. 18), suggest a particular sensitivity of both murine
and human fetal erythropoiesis to the abnormal production of
type I interferon by DNase II-deﬁcient macrophages. F1:V-3 also
developed a later-onset anemia necessitating repeated blood
transfusions. Of possible relevance, in both F1:V-1 and F1:V-3 we
observed increased numbers of circulating erythroblasts sugges-
tive of ineffective erythropoiesis, whilst circulating reticulocyte
counts were inappropriate for the level of circulating hemoglobin.
The mechanism by which loss of DNase II function disturbs adult
erythropoiesis will require further exploration.
The phenotype associated with biallelic mutations in DNASE2
is remarkable for its breadth. After the neonatal period, all three
patients experienced recurrent febrile episodes, and both F1:V-3
and F2:II-4 demonstrated ﬁbrosing hepatitis and membrano-
proliferative glomerulonephritis. Features seen in a single patient
include the deforming arthropathy and vasculitic skin lesions
affecting F2:II-4, while F1:V-3 developed autoantibody-negative
diabetes mellitus, hypogammaglobulinemia and later-onset ane-
mia necessitating long-term insulin replacement, intravenous
immunoglobulin and blood transfusions respectively. In marked
contrast to her younger brother, F1:V-I is essentially clinically
asymptomatic at the age of 10 years, although she has recently
developed signiﬁcant proteinuria and demonstrates a chronic
elevation of ESR and interferon-induced gene transcripts.
Using a new digital ELISA assay, we recorded increased levels
of interferon alpha protein in serum and plasma from all three
patients with mutations in DNase II, and showed that cells from
these patients produce increased amounts of type I interferon and
demonstrate enhanced STAT1 phosphorylation. Concordantly,
we recorded a signiﬁcant type I interferon signature by genome-
wide RNA-Seq analysis, similar to that observed in patients with
other type I interferonopathies. Although mouse data emphasize
the induction of both interferon and non-interferon-mediated
inﬂammation in the absence of DNase II, the post-natal murine
phenotype associated with DNase II deﬁciency in the context of
functional type I interferon signaling has not been deﬁned. By
multiplex analysis we identiﬁed increased expression of a number
of cytokines in patient blood, with a similar pattern of expression
observed in patients with gain-of-function mutations in STING.
Thus, the relative contribution of interferon and non-interferon
dependent pathways to the disease reported here remains unclear.
F2:II-4 has experienced a severe deforming arthropathy possibly
reminiscent of the Dnase2−/− Ifnar1−/− mouse model21. However,
whilst breeding of Dnase2−/− Ifnar1−/− mice on a TNFα or IL-6
null background, or treatment with a monoclonal antibody
against the IL-1 receptor, ameliorated the murine polyarthritis
phenotype22, the use of biologics targeting TNFα and IL-1 sig-
naling has shown minimal clinical efﬁcacy in this patient. Of note,
signiﬁcant joint involvement highly reminiscent of that observed
in F2:II-4 has been seen in patients with gain-of-function muta-
tions in MDA535 (Supplementary Fig. 19).
Beyond infection, systemic lupus erythematous (SLE) was the
ﬁrst human disease to be associated with increased type I inter-
feron signaling36, and mutations in three distinct DNases, DNase
I37, DNase III (TREX1)38 and DNase1L339, 40, have been reported
to predispose to the development of lupus. None of the patients
described here fulﬁll criteria for a diagnosis of SLE. However,
immunocomplex deposition with C1q accumulation was noted in
a renal biopsy of F2:II-4, and all three patients demonstrated
ﬂuctuating elevations of anti-DNA antibodies. Given the current
young age of these patients, we cannot rule out the possibility that
they will develop a more complete lupus phenotype in the future.
The role of foreign nucleic acid in the induction of type I
interferon was recognized over 50 years ago41. More recently, the
importance of mechanisms to avoid the mis-sensing of self
nucleic acid as non-self has been highlighted by the character-
ization of the Mendelian type I interferonopathies3, 7. While
perinatal hematological disturbance, skin vasculitis and non-
deforming arthropathy have been observed in certain type I
interferonopathies, the disorder that we describe here represents a
distinct clinical syndrome. No test to assess type I interferon
status is currently available in routine medical practice, so that the
phenotypic spectrum associated with enhanced type I interferon
signaling will likely broaden as systematic screening, like that
employed here, enters the clinical sphere13, 26. Phenotypic dif-
ferences do not rule out the possibility of a central role for dis-
turbed type I interferon signaling in these various disorders, but
might be explained by differential tissue and temporal expression.
Fig. 4 Interferon signaling in patients with mutations in DNASE2, STING and TREX1, and in controls. a Heat map derived from RNA-Seq expression data of
the top 50 genes ranked by p value (DNASE2-mutated patients vs. controls) with the most signiﬁcant at the top. 41 of these 50 genes are considered as
interferon-stimulated. Lanes 1-14 show individual samples: Lane 1 DNASE2 F1:V-1; lane 2 DNASE2 F1:V-3; lane 3 DNASE2 F1:V-3; lane 4 TREX1 P1; lane 5
TREX1 P2; lane 6 STING P1; lane 7 STING P2, lane 8 STING P3; lanes 9–14 individual healthy controls (HC). b Levels of interferon alpha (IFNα) protein
assayed by digital ELISA in plasma or serum from healthy controls (HC: n= 20), patients with mutations in STING (n= 28 samples from 8 patients),
patients with mutations in TREX1 (n= 4 samples from 4 patients), F1:V-1 (6 samples taken over 3 years), F1:V-3 (7 samples taken over 3 years) and F2:II-4
(2 samples taken over 3 years). Red lines indicate median values. c Analysis of IFNα production by cultured T cells, B cells, natural killer (NK) cells or
monocytes from controls (HC; n= 4), and patients with mutations in DNASE2 (F1:V-1 1 sample; F1:V-3 2 samples), STING (n= 3) or TREX1 (n= 1). d
Increased phosphorylation of STAT1 and STAT3 observed in unstimulated CD3 positive T cells and CD14 positive monocytes from total blood of F1:V-3
compared to a healthy control (HC). e Increased phosphorylation of STAT1 and STAT3 observed in cultured lymphocytic-enriched fractions from F1:V-1
compared to a healthy control (HC), treated or not with the JAK1/2 inhibitor ruxolitinib. Similar results were obtained with cells from F1:V-3. f Increased
expression of selected interferon-stimulated genes in cell fractions enriched for lymphocytes from F1:V-1, F1:V-3 and F2:II-4 with or without ruxolitinib
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On the other hand, the Dnase2−/− mouse clearly indicates both
interferon and non-interferon dependent pathology, so that it is
possible that clinical differences between the disorders currently
classiﬁed as type I interferonopathies might also reﬂect differ-
ential involvement of distinct inﬂammatory pathways. Clariﬁca-
tion of these issues, including how closely individual mouse
models recapitulate their respective human genotypes, will likely
become of increasing relevance as therapies directly targeting type
I interferon signaling are developed42–44.
Methods
Patient and study approval. The study was approved by the Comité de Protection
des Personnes (ID-RCB/EUDRACT: 2014-A01017-40) in France, and the Comi-
tato Indipendente di Bioetica, IRCCS Burlo Garofolo (19/2015; RC17/2014) in
Italy. Investigations were undertaken with written informed parental consent, and
the assent of the probands in both families.
Whole-exome sequencing. DNA was extracted from whole blood samples using
an in-house salting out method. Agilent SureSelect libraries were prepared from 3
µg of genomic DNA extracted from leukocytes, sheared with a Covaris S2 Ultra-
sonicator as recommended by the manufacturer. We used a 51Mb SureSelect
Human All Exon kit V5 (Agilent technologies) for exome capture, with multi-
plexed molecular barcodes for sample traceability. Pooled barcoded exome libraries
were then sequenced on a HiSeq2500 (Illumina) machine, generating 76 + 76 bp
paired-end reads, followed by processing using Genome Analysis Toolkit (GATK),
SAMtools, and Picard (http://www.broadinstitute.org/gatk/guide/topic?name =
best-practices). Calls were made with the GATK HaplotypeCaller, and variants
assessed using the in silico programs SIFT (http://sift.jcvi.org) and Polyphen2
(http://genetics.bwh.harvard.edu/pph2/), and population allele frequencies
obtained from the ExAC (http://exac.broadinstitute.org) and gnomAD (http://
gnomad.broadinstitute.org) databases.
We have screened close to 1000 probands for an interferon signature, and
performed over 2500 interferon signatures in total (as outlined in Rice et al.14). Not
every patient has had genetic analysis, and it is possible that we are not
comprehensively ascertaining DNASE2-mutated patients because, for example,
they are dying due to the perinatal hematological phenotype. However, the clinical
scenario that we describe in this manuscript is apparently rare in our cohort.
Sanger sequencing. Sanger sequencing was performed on DNA from all three
patients and their parents to conﬁrm the DNASE2 variants found by exome
sequencing. The reference sequence used for primer design and nucleotide num-
bering was DNASE2 (NM_001375.2). The exonic regions and ﬂanking intronic
sites of the gene were ampliﬁed by polymerase chain reaction (PCR) using speciﬁc
primers (euroﬁnsgenomics) designed with Primer3plus (http://www.
bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) (Family 1 primers: DNA-
SE2_e3For 5′-TGGCCAGGCTGATTTCTAAC-3′ and DNASE2_e4Rev 5′-
GACAAGGGGAGGAGGAAATG-3′; Family 2 primers: DNASE2_4For 5′-GTA-
GAGATGGGGTTTCGCC-3′ and DNASE2_5Rev 5′-CAAGGGGAGGAG-
GAAATGC-3′).
Liver histology. Fragments of core needle liver biopsy from F1:V-3 were ﬁxed in
buffered formalin, embedded in parafﬁn, cut into 3 µm thick sections and stained
with hematoxylin, eosin, saffron, Perls’ (equal parts mixture of ferrocyanide and
hydrochloric acid than counterstained with ﬁltered neutral red stain), Masson’s
trichrome (stepwise staining in Weigert’s Iron Hematoxylin solution, Biebrich
Scarlet-Acid Fuchsin solution, phosphomolybdic-phosphotungstic acid solution
and aniline blue solution), Sirius red (0.1% solution of Sirius red in saturated picric
acid and then washed in 0.5% acetic acid) and reticulin (0.5% potassium per-
manganate followed by 2% potassium metabisulﬁte, 2% ferric ammonium sulfate,
ammonia silver nitrate solution, 20% unbuffered formalin, 0.2% gold chloride, 2%
potassium metabisulﬁte and 2% sodium thiosulfate). A comparison of the number
and size of Kupffer cells was made between the patient and three age-matched
controls whose histology was normal.
Kidney histology. Biopsy material from F1:V-3 was ﬁxed in buffered formalin,
dehydrated in graded alcohols, embedded in parafﬁn, cut into 3 µm thick and
treated with hematoxylin and eosin, Jones methenamine silver, Masson trichrome,
or periodic acid-Schiff reagent.
Splicing defect characterization. Total RNA was extracted from peripheral blood
mononuclear cells (PBMCs) using RNAqueous-Micro Kit (Ambion). Reverse
transcription was performed using the High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). For visualization of mutation-induced defective splicing,
cDNA from patient and control PBMCs was ampliﬁed with primers encompassing
exon 4 of human DNASE2 (DNASE2_e3For 5′-TGCCAGCTCTTAGAGGGT-3′
and DNASE2_e5Rev 5′-AGGGTTCTTGGCTAACGTGGTG-3′). The faint band of
wild-type size was puriﬁed from the gel using MicroElute Gel Extraction Kit from
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Omega, cloned in a pGEMT vector from Promega and sequenced by Sanger
sequencing using the same primer pair as above. For exon 4 and exon 5 in family
F1, quantitative reverse transcription polymerase chain reaction (qPCR) analysis
was performed using TaqMan Universal PCR Master Mix (Applied Biosystems) on
a ViiA 7 Real-Time PCR system, and cDNA derived from 40 ng total RNA. Using
TaqMan probes for DNASE2 exon 4 (Hs00172391_m1) and DNASE2 exon5
(Hs00923081_m1), the relative abundance of each target transcript was normalized
to the expression level of HPRT1 (Hs03929096_g1) and 18 S rRNA
(Hs999999001_s1), and assessed with the Applied Biosystems StepOne Software
v2.1 and DataAssist Software v.3.01.
ISG RNA expression in total blood. Whole blood was collected into PAXgene
tubes. We used a PreAnalytix RNA isolation kit and RNA concentration, assessed
with a spectrophotometer (FLUOstar Omega, Labtech), to extract total RNA. We
performed quantitative reverse transcription polymerase chain reaction (qPCR)
analysis using the TaqMan Universal PCR Master Mix (Applied Biosystems), and
cDNA derived from 40 ng total RNA. Using TaqMan probes for IFI27
(Hs01086370_m1), IFI44L (Hs00199115_m1), IFIT1 (Hs00356631_g1), ISG15
(Hs00192713_m1), RSAD2 (Hs01057264_m1), and SIGLEC1 (Hs00988063_m1),
the relative abundance of each of 6 ‘interferon score’ target transcripts was nor-
malized to the expression level of HPRT1 (Hs03929096_g1), and 18 S rRNA
(Hs999999001_s1), assessed using the Applied Biosystems StepOne Software v2.1
and DataAssist Software v.3.01. Individual data were expressed relative to a single
calibrator for each of the six probes. RQ (relative quantiﬁcation) is equal to 2−ΔΔCt,
i.e., the normalized fold change relative to the control data. The median fold change
of the 6 genes compared to the median of 29 previously collected healthy controls is
used to create an interferon score for each individual, with an abnormal interferon
score being deﬁned as greater than +2 SD above the mean of the control group, i.e.,
2.466.
For the extended interferon analysis, the relative abundance of target
transcripts, was measured using the additional TaqMan probes Ly6E
(Hs00158942_m1), MX1 (Hs00895598_m1), USP18 (Hs00276441_m1), OAS1
(Hs00973637_m1), IFI44 (Hs00197427_m1), IFI6 (Hs00242571_m1), IFIT3
(Hs00155468_m1), IRF7 (Hs00185375_m1) and STAT1 (Hs01013989_m1), was
normalized to the expression level of HPRT1 (Hs03929096_g1) and 18 s
(Hs999999001_s1) and assessed with Applied Biosystems StepOne Software v2.1.
ISG RNA expression in PBMCs. Messenger RNA from treated and non-treated
cultured cells were quantiﬁed by qRT-PCR using TaqMan probes for IFI27
(Hs01086370_m1), IFI44L (Hs00199115_m1), ISG15 (Hs00192713_m1), and
SIGLEC1 (Hs00988063_m1), the relative abundance of each target transcript
normalized to the expression level of HPRT1 (Hs03929096_g1), and assessed with
the Applied Biosystems StepOne Software v2.1.
ISG RNA expression analysis. 1 × 106 cells were lysed in 350 µL RLT-Buffer
(Qiagen), frozen at −80 °C, thawed, supplemented with 1 volume 70% Ethanol and
loaded onto a Zymo III column (Zymo). The column was then washed with
RW1buffer (Qiagen) and then RNA wash buffer (Zymo) and eluted with DEPC
water. Samples were then subjected to DNase I digestion and reverse transcription
with OligodT primers and RevertAid (all from ThermoFischer, Waltham, MA,
USA) according to the manufacturer’s instructions. RT-PCR was performed using
with 5x EvaGreen QPCR-Mix II (ROX) (Biobudget, Krefeld, Germany). Primers
for IFIT1, IFI16 and IFI44 were designed using NCBI primer blast. Sequences used
were: IFIT1 forward 5′-GTGCTTGAAGTGGACCCTGA-3′, IFIT1 reverse 5′-
CCTGCCTTAGGGGAAGCAAA-3′, IFI16 forward 5′-ATATCCTTCA-
GAGGCCAGCA-3′, IFI16 reverse 5′-ATCTGAGGAGTGTGGGGATG-3′, IFI27
forward 5′- TGCCCATGGTGCTCAGTG-3′ and IFI27 reverse 5′- GAGAGTC-
CAGTTGCTCCCAG-3′. Primers were validated with melting curve and agarose
gel analysis and tested for efﬁciency using cDNA dilution.
Gene expression analysis by RNA sequencing. Whole transcriptome expression
analysis was performed using one sample from F1:V-1 and two samples from F1:V-
3 plus three age-matched controls, three patients mutated in TMEM173 and two
patients mutated in TREX1 (Supplementary Table 5). We extracted total RNA from
blood samples in PaxGene tubes (Qiagen, Valencia, CA), and analyzed RNA
integrity with an Agilent 2100 Bioanalyzer. We used the Illumina TruSeq RNA
Sample Preparation Kit (Illumina) for mRNA puriﬁcation and fragmentation,
complementary DNA synthesis and target ampliﬁcation. cDNA libraries were then
pooled and sequenced on a HiSeq 2000 Illumina platform (Illumina). The RNA-seq
workﬂow was as follows: quality assessment by FastQC (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/), quality ﬁltering with Trimmo-
matic (PMID: 24695404), read mapping with STAR (PMID: 23104886) to hg38,
read counting into genes with HTSeq (PMID: 25260700) using annotation from
GENCODE v24 (http://www.gencodegenes.org/), normalization and differential
expression analysis with DESeq2 (PMID: 25516281). Hierarchical clustering was
conducted using the Partek software (version 6.6). Patients and healthy controls
were compared using ANOVA analysis, and a list of the 2-fold up or down-
regulated genes was generated. The statistical signiﬁcance level adopted was p<
0.05. Gene lists were uploaded into Ingenuity Pathway Analysis (http://www.
ingenuity.com) in order to determine differentially regulated canonical pathways in
the patients. Results for interferon-regulated genes are shown as a heat map, with
shades of red denoting upregulated genes and shades of blue denoting down-
regulated genes.
siRNA knockdown of DNASE2. siRNA knockdown was performed in primary
ﬁbroblasts via repetitive transient transfection using with 150 nM of SMARTpool
ON-TARGETplus siRNA (Dharmacon) targeting DNASE2 (NCBI refseq:
NM_001375) or a negative control. siRNAs were transfected via complexation with
Lipofectamine 2000 (Life Technologies) according to the manufacturer’s instruc-
tions. Fibroblasts were transfected twice, with the second transfection after 48 h.
DNase 2 assays were performed 24 h after the second transfection. Knockdown
efﬁciency was evaluated by quantitative real-time PCR. The DNASE2 primers used
were: (forward) 5′-TCGCCTTCCTGCTCTACAAT-3′ and (reverse) 5′-
CCCATCTTCGAGAACTGAGC-3′.
Plasmids. Human DNase II gene ORF cDNA clone expression plasmid with a
C-terminal Myc-FLAG tag, pCMV6-RC209573, was purchased from OriGene
(OriGene Technologies, Rockville, Maryland, USA). The deletion of exon 4 and the
mutations c.347G>C and c.362A>T were introduced into pCMV6-RC209573 via
site-directed mutagenesis. The deletion of exon 4 was performed using the Q5 Site-
Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA, USA) according to
the manufacturer’s instructions. The point mutations were introduced via whole
plasmid PCR with Pfu Ultra (Stratagene). The primers used were: (deletion exon
4 sense) 5′-GCAAGCAGCTGACCTACAC-3′, (deletion exon 4 antisense)
5′-CCTTCGTGTGCCCACGCA-3′, (c.347G>C sense) 5′-AAGGAGCAGGA-
CAGCCTTCGTGTGCCC-3′, (c.347G>C antisense) 5′-GGGCACACGAAGG
CTGTCCTGCTCCTT-3′, (c.362A>T sense) 5′-GCCCCCATCGTGGACAAGG
AGCAGGAC, and (c.362A>T antisense) 5′- GTCCTGCTCCTTGTCCACGAT
GGGGGC-3′. Sequencing conﬁrmed that the respective mutations were incorpo-
rated, with no other alteration in the construct.
For lentivirus expression, human DNase II cDNA was transferred from
pCMV6-RC209573 via SalI/NotI fusion to a modiﬁed version of pLenti6
(Invitrogen, ThermoFisher Scientiﬁc, Waltham, MA) with an elongation factor-1a
(EF1a) promoter and encephalomyocarditis virus IRES sequence followed by an
eGFP sequence and a blasticidin/SV40 promoter resistance cassette.
For CRISPR-Cas9-based editing of human DNase II, the gRNA
GGCACTCATCAACAGCCCGG(AGG) was selected with the CRISPR design tool
(Zhang Lab, MIT, crispr.mit.edu) and introduced into an EF1a-Cas9-U6-sgRNA
expression plasmid via Gibson assembly45.
All DNase II degradation assays were performed using an empty pBluescript
(SK-) bacterial vector.
CRISPR-Cas9 genome editing. A CRISPR/Cas9/gRNA plasmid targeting
DNASE2 was introduced into HEK293FT (Invitrogen) using TransIT-LT1
Transfection Reagent (Mirus Bio, Madison, Wisconsin) according to the manu-
facturer’s instructions. Cells were then subjected to limited dilution and seeded as
single-cell colonies. After expansion, DNase II-deﬁcient clones were identiﬁed via
Sanger sequencing. A clonal cell line with a heterozygous 7 bp deletion in Exon 2
was used for the experiments in this manuscript.
Lentivirus expression and lentiviral transduction. Lentiviral particles were
generated as previously described46. In brief, lentiviral transduction was
performed using a second generation lentiviral vector pLenti (Invitrogen), which is
a poor stimulator of the type 1 interferon response even during acute infection47
and which are not capable of replication. Viral supernatants were then subjected to
ultracentrifugation using a Beckman Coulter SW32 rotor at 21000xg for 2 h.
Viral pellets were then resuspended in DMEM and added to primary human
ﬁbroblasts at an MOI of 100. After 2 days, positive cells were selected using
blasticidin.
Puriﬁcation and quantiﬁcation of DNase II protein. Human DNase II constructs
with a C-terminal FLAG sequence were introduced into DNase-II-deﬁcient
HEK293FT via calcium phosphate transfection. After 36 h, the cells were subjected
to cytosolic lysis with a buffer containing 50 mM Tris HCl, pH 7.4, 150 mM NaCl,
50 mM EDTA, 1% TRITON X-100, and a protease inhibitor cocktail (cOmplete
Protease Inhibitor Cocktail Tablets, Roche). Nuclei were removed via centrifuga-
tion, and the cytosolic supernatant was fractionated with ammonium sulfate and
resuspended in 50 mM Tris HCl, pH 7.4, with 150 mM NaCl, 1 mM EDTA. The
samples were then subjected to afﬁnity immunoprecipitation with Anti-FLAG M2
Agarose Beads (Sigma) and eluted with FLAG Peptide (Sigma) according to the
manufacturer’s instructions. The eluted fractions were precipitated with ammo-
nium sulfate, resuspended and dialyzed with SpectraPor #4 tubing MWCO 12–14
kDa (Carl Roth, Karlsruhe, Germany) against 40 mM Tris-HCl 7.4, 25 mM EDTA,
100 mM NaCl, 1 mM DTT to remove FLAG Peptide and residual ammonium
sulfate. Proteins were quantiﬁed using an in-house developed FLAG-based ELISA
assay. In brief, high-binding plates were coated with the proteins of interest and
deﬁned amounts of puriﬁed IL-1b-FLAG were used as a standard. Plates were then
blocked with 1% BSA overnight, and FLAG-tagged proteins were detected using
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HRP-coupled Anti-FLAG M2 antibody. These results were then veriﬁed via PAGE
electrophoresis and immunoblotting with Anti-FLAG M2 antibody.
Activity of puriﬁed DNase II protein and in cell lysates. Puriﬁed DNase II
protein was combined with 1 µg plasmid DNA and incubated at pH 5.0 with 60
mM NaOAc and 50 mM EDTA for 1 h. Samples were then neutralized with a
loading buffer containing 0.25% bromophenol blue, 25% glycerol, 80 mM Tris-
HCl, pH 8, and 5 mM EDTA and subjected to electrophoresis in a 1% agarose gel
containing 0.0001% SybrSafe (ThermoFisher, Waltham, MA, USA). DNA was
visualized with a Licor® Fc imaging system (Licor, Lincoln, Nebraska, USA).
DNase II activity in patient ﬁbroblasts was measured using a modiﬁed version
of the protocol from Howell48. In brief, 2 × 106 ﬁbroblasts were lysed in 100 µL lysis
buffer, containing 1% Triton-X, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl and 25
mM EDTA. Nuclei were removed by centrifugation, Puriﬁed plasmid DNA was
diluted with assay buffer (60 mM sodium acetate, pH 5, 50 mM) to a ﬁnal amount
of 0.4 g per 21 µL reaction and aliquoted. Cellular supernatants were diluted 1:5
into the DNA solution and incubated at 37 °C as indicated. Samples were then
neutralized with loading buffer, subjected to agarose gel electrophoresis and imaged
as described above.
Determination of the rate of change of optical density was performed with a
modiﬁed, microscaled version of the protocol from Kunitz49. In brief, 1 µg of
plasmid DNA was incubated with the indicated concentrations and types of DNase
II and 0.1 M NaOAc buffer (pH) in a total volume of 3 µL at 37 °C in a Biotek Take
3 microplate (Biotek, Winooski, Vermont, USA), and the absorbance at 260 nm
was measured once per minute.
Stimulation of primary human ﬁbroblasts. Fibroblasts were seeded at 2 × 105
cells per well in a 96-well plate. After 16 h, the cells were stimulated. cGAMP
transfection was performed via digitonin permeabilization as previously descri-
bed50 In brief, cells were permeabilized at 37 °C for 30 min with 5 µM 2′-3′cGAMP
in 50 mM HEPES pH 7.0, 100 mM KCl, 3 mM MgCL2, 0.1 mM DTT, 85 mM
Sucrose, 0.2% BSA, 1 mM ATP, 0.1 mM GTP and 10 µg/mL Digitonin. 5′ tripho-
sphate dsRNA (5′ pppRNA) was created via in vitro transcription using a com-
mercial T7 in vitro transcription kit with the template 5′-
TTGTAATACGACTCACTATAGGGACGCTGACCCAGAAGATCTACTA-
GAAA TAGTAGATCTTCTGGGTCAGCGTCCC-3′ as in reference51. For sti-
mulation with dsDNA and 5′ pppRNA, 200ng was transfected per well with
lipofectamine 2000 (ThermoFisher) according to the manufacturer’s instructions.
STAT phosphorylation assay staining. Peripheral blood mononuclear cells
(PBMCs) were treated or untreated with ruxolitinib 1 µM for 2 h. Cells were ﬁxed
using Beckman Coulter PerFix Expose Fixation Buffer (10 min at room tempera-
ture) and then permeabilized using BC PerFix Expose Permeabilizing Buffer (5 min
at 37 °C). Cells were stained with FITC-anti-STAT1 pY701 (BD Bioscience, cat:
612596, 4a, 1:5), PE-anti-STAT1 pY701 (BD Bioscience, cat: 612564, 4a, 1:5) or
FITC-anti-STAT3 pY705 (BD Bioscience, cat: 612564, 4a, 1:5) and cell surface
markers APC-CD3 (Miltenyi Biotec, cat: 160-109-462, REA613, 1:30) and APC-
Alexa750-CD14 (Beckman Coulter, cat: B92421, RM052, 1:30)) for 1 h at room
temperature protected from light. Flow cytometry analysis was performed on a
Gallios Beckman Coulter ﬂow cytometer. Results were analyzed using Kaluza
software v1.3.
Quantiﬁcation of circulating protein biomarkers. Serum or plasma concentra-
tion of the following 65 immune monitoring biomarkers, APRIL, BAFF, BLC,
CD30, CD40L, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, FGF-2, Fractalkine, G-CSF,
GM-CSF, Gro α, HGF, IFN-α, IFN-ɣ, IL-10, IL-12p70, IL-13, IL-15, IL-16, IL-17A,
IL-18, IL-1 α, IL-1β, IL-2, IL-20, IL-21, IL-22, IL-23, IL-27, IL-2R, IL-3, IL-31, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, I-TAC, LIF, MCP-1, MCP-2, MCP-3, M-CSF,
MDC, MIF, MIG, MIP-1 α, MIP-1β, MIP-3α, MMP-1, NGF-β, SCF, SDF-1α, TNF-
β, TNF-α, TNF-R2, TRAIL, TSLP, TWEAK, and VEGF-A, were assessed in sam-
ples from patients and healthy donors. Frozen sera or plasma were thawed and
spun (1000 × g, 5 min) immediately before starting the experiment. Quantiﬁcation
was performed based on the Luminex xMAP technology (Luminex Corp., Austin,
TX, USA), using the Immune Monitoring 65-Plex Human ProcartaPlex Panel
(ThermoFischer Scientiﬁc, Waltham, MA, USA), according to the manufacturer’s
instructions. Plates were analyzed on a Bioplex 200 analyzer (Biorad, Hercules, CA,
USA). Concentrations were calculated from the raw data using the Five-Parameter
Logistic (5PL) equation on the GraphPad Prism6 software (GraphPad Software,
Inc., La Jolla, CA, USA). Heat maps were made with the R package ctc: Cluster and
Tree Conversion and imaged by Java Treeview software.
Single analyte ELISA assays. TNFα, IL-1β and IL-6 were measured by standar-
dized ELISA assay (Invitrogen, KAC1751, KAC1211, KAC1261 respectively) in the
diagnostic laboratory of the Hôpital Necker-Enfants Malades, and compared to a
normal range of controls for each cytokine.
Interferon alpha in serum and supernatant. As reported by Rodero et al.26, a
Simoa interferon alpha (IFN-α) assay was developed using a Quanterix Homebrew
Simoa assay and two autoantibodies speciﬁc for IFN-α isolated and cloned from
two APS1/APECED patients recently described24. The 8H1 antibody clone was
used as a capture antibody after coating on paramagnetic beads (0.3 mg/mL), and
the 12H5 was biotinylated (biotin/Ab ratio = 30/1) and used as the detector.
Recombinant IFN-α17/αI (PBL Assay Science) was used as a standard curve after
cross-reactivity testing. The limits of detection (LOD) were calculated by the mean
value of all blank runs + 3SDs and was 0.23 fg/mL.
Cell sorting and culture for interferon alpha dosage. Peripheral blood mono-
nuclear cells (PBMCs) were isolated from blood using lymphocyte separation
medium. Just after isolation, PBMCs were labeled with CD3 Krome Orange
(Beckman Coulter, cat: B00068, UCHT1, 1:30), CD19 PE-Cy7 (BD Bioscience, cat:
557835, SJ25C1, 1:100), CD56 FITC (Miltenyi Biotec cat: 130-100-746, REA196,
1:30) and CD14 APC-Alexa Fluor 750 (Beckman Coulter, cat: B92421, RM052,
1:30). PBMC subsets were isolated using a BD FACS Aria II. Purity of the cell
sorting was veriﬁed for 9 individual donors, and was high for all populations
(mean± SD for CD3: 95.73% ± 3.02; B cells: 97.5% ± 2.3; NK: 97.9% ± 1.6;
monocytes: 97.7% ± 2.6). After sorting, cells were cultured at 1,500,000 cells per mL
in 96 wells plates with 100 µL of RPMI SVF10% for 48 h. Supernatant was isolated
from non-adherent cells and debris by centrifugation (5 min, 10,000 × g), and
stored at −80 °C until analyzed on the Simoa platform.
Erythroid liquid culture. Erythroid cells were generated in vitro from peripheral
blood circulating CD34+ cells obtained from the cord blood of healthy donors.
Isolated CD34+ progenitors (Miltenyi Biotec CD34 Progenitor Cell Isolation Kit)
were grown in the presence of 100 ng/mL IL-6, 10 ng/mL IL-3 and 100 ng/mL stem
cell factor (SCF) for 7 days. On day 7, erythroid progenitors were switched to a
second phase of culture allowing the differentiation and maturation of erythro-
blasts: thus, cells were cultured in the presence of 10 ng/mL IL-3, 50 ng/mL SCF
and 0.2 U/mL erythropoietin (EPO) in IMDM (Gibco cell culture) supplemented
with 15% BIT 9500 (Stem Cell Technologies), as previously described52. Cells were
then cultured in the presence of 3 different doses of interferon alpha 2 (0, 100, and
1000 IU/L).
Western blot analysis. Proteins were extracted from monocyte-derived macro-
phages enriched from PBMCs by plastic adhesion and from transfected HEKs
using lysis buffer (RIPA) supplemented with 1% protease inhibitor and 1%
phosphatase inhibitor (all from ThermoFisher Scientiﬁc, Waltham, Massachusetts,
USA). Bolt LDS Sample Buffer (4×) (Novex Life Technologies) and Bolt Sample
Reducing agent (10×) (Novex Life Technologies) were added to protein lysates,
samples resolved on 8% Bolt Bis-Tris Plus gels (ThermoFisher Scientiﬁc, Waltham,
Massachusetts, USA), and then transferred to nitrocellulose membrane (#IB23002,
ThermoFisher Scientiﬁc, Waltham, Massachusetts, USA). Membranes were
blocked by incubation with 3% non-fat milk powder in TBS and primary anti-
bodies were incubated overnight. The appropriate Infrared Dye (IRDye)-con-
jugated secondary antibody (IRDye 680RD Goat Anti-Mouse IgG C/N 926-68070
or IRDye 800CW Goat Anti-Rabbit IgG C/N 926-32211; dilution 1:10,000;
both from Li-Cor, Lincoln, Nebraska, USA) was incubated with the membrane
before the detection of antibody binding by Licor Odyssey CLx system
(Li-Cor, Lincoln, Nebraska, USA). Proteins were detected with polyclonal anti-
DNASE2 (ab8119, dilution 1:500) and Vinculin (EPR8185, ab129002, dilution
1:50000) antibodies (both from Abcam, Cambridge, UK); monoclonal mouse
mouse anti-β-Actin (Cell Signaling, Danvers, Massachusetts, USA, 8H10D10,
1:10,000) antibody. DNase II is glycosylated at multiple sites, giving a size at
around 47 kDa53.
Protein modeling: PDB reference. Experimental 3D structures of was based
on a previously published structure prediction17 and analyzed using Chimera
(http://www.cgl.ucsf.edu/chimera/).
URLs. UCSC Human Genome Browser, http://genome.ucsc.edu/; Ensembl,
http://www.ensembl.org/; dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/;
Exome Variant Server, NHLBI Exome Sequencing Project (ESP), http://snp.gs.
washington.edu/EVS/; Exome Aggregation Consortium (ExAC), http://exac.
broadinstitute.org (accessed January 2017); Clustal Omega, http://www.ebi.ac.uk/
Tools/msa/clustalo/; Alamut, http://www.interactive-biosoftware.com/; GraphPad,
http://www.graphpad.com/.
Data availability. All relevant non-patient sensitive data are available from the
authors. RNA-seq data are available at ArrayExpress E-MTAB-5735.
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